Moderna reportedly received over $1.4 billion from the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services (BARDA) to produce 100 million doses of its COVID-19 vaccine.
AHF also calls on Moderna and all other drug companies receiving taxpayer funds and taxpayer-funded research to make the COVID-19 vaccine available to the international community by withholding enforcement of their patents in order to make this lifesaving medicine available to rich and poor countries equally.
In a related action, the advocacy group Public Citizen said in a press statement that Moderna should "... dedicate its technology to the World Health Organization (WHO) so that the world can prepare to make vaccines for billions of people, rather than permit vaccine apartheid where only wealthy countries have vaccine access."
AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to over 1.4m people in 45 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Eastern Europe.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV